Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: A video-capsule endoscopy study

Bone Marrow Transplantation

Volumn 42, Issue 5, 2008, Pages 337-343

  Tsirigotis, P ^a   Triantafyllou, K ^b   Girkas, K ^a   Giannopoulou, V ^a   Ioannidou, E ^a   Chondropoulos, S ^a   Kalli, T ^b   Papaxoinis, G ^a   Pappa, V ^a   Papageorgiou, E ^a   Economopoulos, T ^a   Ladas, S D ^b   Dervenoulas, J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PALIFERMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CAPSULE ENDOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; ENGRAFTMENT; ENTERITIS; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTION; INTESTINE MUCOSITIS; LARGE CELL LYMPHOMA; LUNG INFECTION; LUNG MYCOSIS; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NOSE CONGESTION; PRIORITY JOURNAL; PRURITUS; STEM CELL MOBILIZATION; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPSULE ENDOSCOPY; CARMUSTINE; CYTARABINE; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL DISEASES; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; PODOPHYLLOTOXIN; TRANSPLANTATION, AUTOLOGOUS;

EID: 52149094094     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.168     Document Type: Article

References (28)

1. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8: 33-39.
2. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186-5193.
3. Balzan S, de Almeida Quadros C, de Cleva R, Zilberstein B, Cecconello I. Bacterial translocation: Overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2007; 22: 464-471.
4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19 2201-2205.
5. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
6. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 33: 338-343.
7. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
8. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
9. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004; 91: 69-136.
10. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radio-therapy-induced mucositis. Ann Oncol 2007; 5: 817-826.
11. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
13. Brennan MT, von Bultzingslowen I, Schubert MM, Keefe D. Alimentary mucositis: Putting the guidelines into practice. Support Care Cancer 2006; 14: 573-579.
14. Triantafyllou K, Dervenoulas J, Tsirigotis P, Latias SD. The nature of small intestinal mucositis. A video-capule endoscopy study. Accepted for publication in Support Care Cancer 2008; e-pub ahead of print.
15. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
16. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452-1458.
17. Sonis ST. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers? Nat Clin Pract Oncol 2005; 2 134-135.
18. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004; 100 (Suppl 9): 1995-2025.
19. Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157-1159.
20. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: Comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43-48.
21. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581-587.
22. Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665-672.
23. Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
24. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939.
25. Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50: 53-58.
26. Brauchle M, Madlener M, Wagner AD, Augermeyer K, Lauer U, Hofschneider PH et al. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996; 149: 521-529.
27. Lutgens L, Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: An emerging role for plasma citrulline. World J Gastroenterol 2007; 13: 3033-3042.
28. Shapira M, Adler SN, Jacob H, Resnick IB, Slavin S, Or R. New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy. Haematologica 2005; 90: 1003-1004.